Targeting activated partial thromboplastin time of unfractionated heparin: the role of clinical pharmacist at the cardiac care unit
Authors/Creators
- 1. Department of Clinical Pharmacy, Baghdad Teaching Hospital, Baghdad, Iraq
- 2. University of Baghdad, Baghdad, Iraq
Description
Background: Unfractionated heparin (UFH) requires precise monitoring, primarily via activated partial thromboplastin time (aPTT), to achieve therapeutic anticoagulation and minimize complications. Optimizing UFH therapy demands robust monitoring strategies and collaborative involvement of healthcare professionals, particularly pharmacists.
Objective: This study aimed to evaluate aPTT levels in patients receiving UFH and determine the impact of clinical pharmacists on achieving target aPTT in a cardiac care unit (CCU).
Patients and methods: A prospective observational study was conducted in the CCU of Baghdad Teaching Hospital from February 2023 to January 2024, enrolling patients prescribed UFH.
Results: Of 307 patients, only 21% (n = 65) initially reached therapeutic aPTT levels. Notably, only 1 of 47 patients receiving subcutaneous UFH achieved target aPTT (P = 0.009). Clinical pharmacists performed 80 interventions, resulting in a statistically significant improvement in mean aPTT from 44.1 ± 24.8 to 46.7 ± 24 (P < 0.001). This increased the percentage of patients within the therapeutic range from 21% (n = 65) to 29% (n = 90).
Conclusion: Clinical pharmacist interventions significantly improved aPTT targeting for UFH in the CCU, increasing therapeutic achievement rates despite initially suboptimal levels and highlighting their value in optimizing anticoagulation therapy.
Files
PHAR_article_163936.pdf
Files
(532.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:c4a66f5d23ac3bd948f7de17f41eaf8f
|
459.4 kB | Preview Download |
|
md5:28ed847649781d3352733a14410660ab
|
73.4 kB | Preview Download |
Additional details
References
- Alsulaiman D, Sylvester K, Stevens C, Carter D (2016) Comparison of time to therapeutic aPTT after pharmacy alerts. Hosp Pharm 51(8): 656–661. https://doi.org/10.1310/hpj5108-656
- Barry R, Stevens CA, Huynh T, Lerner D (2021) Impact of protocolized pharmacist intervention on critical aPTT values with heparin. J Pharm Technol 37(5): 225–233. https://doi.org/10.1177/87551225211031923
- Becattini C, Agnelli G (2020) Acute treatment of venous thromboembolism. Blood 135(5): 305–316. https://doi.org/10.1182/blood.2019001881
- Biscup-Horn PJ, Streiff MB, Ulbrich TR, Nesbit TW, Shermock KM (2008) Impact of an inpatient anticoagulation management service on clinical outcomes. Ann Pharmacother 42(6): 777–782. https://doi.org/10.1345/aph.1L027
- Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Collet JP, Costa F, Ibanez B, Juarez-Orozco LE, Mauri J, Peltola M, Petrides GP, Phoenix T, Ranieri M, Salvioni I, Scoccia A, Sechtem U, Storey RF, Windecker S, Kristensen SD (2023) 2023 ESC Guidelines for acute coronary syndromes. Eur Heart J 44(38): 3720–3826. https://doi.org/10.1093/eurheartj/ehad191
- Chakraborty DS, Kar B, Choudhury S, Ghosh A, Samanta K, Hazra A (2022) Knowledge, attitude and practice survey regarding high alert medication among resident doctors in Eastern India. Curr Drug Saf 17(4): 375–381. https://doi.org/10.2174/1574886317666220207123704
- Fadheel QJ, Naser RT, Al-Hindy HA (2022) Evaluation of anticoagulant prescribing in Iraqi patients. HIV Nurs 22(1): 71–76.
- Hogg K, Weitz J (2022) Blood coagulation and anticoagulant drugs. In: Brunton LL, Knollmann BC (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th edn. McGraw-Hill, New York, 604–607.
- IASJ (2025) Iraqi Academic Scientific Journals (IASJ). https://iasj.rdd.edu.iq/journals/ [Accessed 13 Aug 2025]
- Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing HL, Harjola TA, Hentrich E, Khaar S, Lankeit M, Nielsen JD, Sanchez O, Schuld B, Skride V, Tomek A, Vlachopoulos CV, Windecker S, Zamorano JL (2020) 2019 ESC Guidelines for acute pulmonary embolism. Eur Heart J 41(4): 543–603. https://doi.org/10.1093/eurheartj/ehz405
- Kuitunen S, Saksa M, Tuomisto J, Holmström AR (2023) Medication errors related to high-alert medications in a paediatric university hospital: a cross-sectional study. BMC Pediatr 23(1): 548. https://doi.org/10.1186/s12887-023-04333-2
- Levy JH, Connors JM (2021) Heparin resistance—clinical perspectives. N Engl J Med 385(9): 826–832. https://doi.org/10.1056/nejmra2104091
- Loria G (2012) Reduction of harm from high risk medications. Apollo Med 9(2): 160–165. https://doi.org/10.1016/j.apme.2012.05.001
- Lysogorski MC, Hassan AK, Lampkin SJ, Geisler R (2017) Pharmacy monitoring of intravenous heparin. Int J Clin Pharm 39(4): 844–850. https://doi.org/10.1007/s11096-017-0482-y
- McRae HL, Militello L, Refaai MA (2021) Updates in anticoagulation therapy monitoring. Biomedicines 9(3): 262. https://doi.org/10.3390/biomedicines9030262
- Niccolai CS, Hicks RW, Oertel L, Francis JL, Heparin Consensus Group (2004) Unfractionated heparin: focus on a high-alert drug. Pharmacotherapy 24(8 Pt 2): 146S–155S. https://doi.org/10.1592/phco.24.12.146S.36107
- Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK (2016) Practical management of heparin anticoagulants. J Thromb Thrombolysis 41(1): 165–186. https://doi.org/10.1007/s11239-015-1315-2